Plain-English translation of NCT07392255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new treatment called CTx001, which is injected directly into the back of the eye to help people with geographic atrophy—a type of age-related vision loss where the central part of the retina slowly breaks down. The medication is designed to target inflammation in the eye that may be driving this condition. Researchers want to find out if this treatment is safe and whether it can slow down or stop vision loss in people with this disease.
Geographic atrophy is a progressive condition that gradually steals central vision, and there are currently no FDA-approved treatments that can stop or reverse it. This study exists to test whether this new medication can offer hope to patients who otherwise face continued vision decline.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a single injection of the medication into the back of your study eye during a surgical procedure. You'll then be closely monitored with regular clinic visits for 2 years, during which doctors will measure your vision and eye health through imaging and vision tests. After the first 2 years, you'll continue with annual follow-up visits for up to 5 years total. The study will involve multiple eye exams, imaging scans, and vision tests to track whether the treatment is helping and to monitor for any side effects.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States
United Kingdom